Ipsen : ESMO 2021, Cabometyx demonstrates sustained 78% reduction in risk of disease progression or death in people living with uncom-mon form of thyroid cancer

PARIS, FRANCE - Ipsen (Euronext: IPN; ADR: IPSEY) announced presentation of new analyses at the European Society for Medical Oncology (ESMO) Congress 2021 across different forms of cancer for people treated with Cabometyx (cabozantinib). Of note, the final analysis of the pivotal Phase III COSMIC-311 trial (Abstract LBA67) will be presented, with Cabometyx demonstrating a clinically meaningful, sustained efficacy benefit versus placebo in people living with previously treated radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

With a median follow-up of 10.1 months, Cabometyx continued to demonstrate superior median progression-free survival (mPFS) with a reduction in the risk of disease progression or death of 78% versus placebo (hazard ratio [HR]: 0.22, 96% confidence interval [CI]: 0.15-0.32; p

(C) 2021 Electronic News Publishing, source ENP Newswire